Bridge to Life United States

There are multiple suppliers and distributors of the organ preservation solutions developed by Drs. Belzer and Southard at the University of Wisconsin. All patents on the formulations used in Belzer UW® Solutions (cold storage and machine perfusion) expired in 2006. Bridge to Life has an exclusive trademark license from the Wisconsin Alumni Research Foundation (WARF) for the trademark Belzer UW®.

In fact, WARF holds an equity position in Bridge to Life Ltd., a WARF startup company. We proudly honor the name of Dr. Belzer and the institution that developed the UW organ preservation solution, which is still the “gold standard” in organ preservation.

Aaron Gilchrist
Global Director of Business Development 

Broadview Ventures United States

In 2008 the Leducq Family Trust established Broadview Ventures, Inc.(Broadview). Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Nishant "Nish" Rastogi shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

Mr Nishant Rastogi
Investor 

Business France United States

Mrs Elsa Rive
International Trade Advisor 

Business France

Hugues Moreaux

C. Texdev France

CTEXDEV develops Augmentative and Alternative Communication (AAC) applications called CommunicoTool, to help non-verbal individuals to communicate.

Industry sectors  E_health


Therapeutics Area  Psychiatry/Psychology

Our innovative solution

 CommunicoTool is an Augmentative and Alternative Communication (AAC) application that provide language communication features including: pictures and pictograms, prerecorded voice, speech synthesis, speech/pain assessment, time management. The application is fully configurable by the end users. Our service is available in French and English in a bilingual version.

Problem  solved

CommunicoTool is an application for tablets suitable for patients with ASD, Stroke, LAS, Cerebral pulsy, with language and communication disorders. Just for ASD, The CDC (Centers for Disease Control and Prevention) estimates about 1 percent of the world population (7 billion) has autism spectrum disorder, and more than 25% of them are non-verbal. 

Market segments

ASD / Stroke / LAS / Cerebral pulsy

Key value proposition

Accessibility / price / Innovation / Configurable

Frederic Guibet
CEO - Founder 

Care Labs France

Care Labs Edition, management and marketing of prepaid voucher : healthcare voucher Industry sectors E health Therapeutics Area Dental and Oral Health
Dermatology
Nutrition and Weight Loss
Orthopedics/Orthopedic Surgery
Psychiatry/Psychology
Your innovative solution

CHEQUE SANTE

Which problem are you solving ?

The costs of healthcare become more and more disabling for the modern-day families. Because of these costs, they tend to avoid taking medical appointments. Our objective is to allow every individual to be the master of his own health capital.

Target market segments

Firms, Works Council, Mutual insurance companies, Insurances?

Key value proposition

Prepaid voucher, Online appointment setting, Intelligent health record, Directory of the healthcare professionals

Vincent DAFFOURD
PrĂ©sident 

Center for Human Reproduction United States

Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA)immunological problems affecting reproduction, repeated pregnancy lossendometriosispolycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

Dr Norbert Gleicher
Medical Director 

CereSpir United States

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.

Professor Daniel Chain
President & Chief Executive Officer 

Chromocell Corporation United States

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

Dr Tina Garyantes
Vice President, Therapeutics 

Citi United States

The Private Company Access team leverages Citigroup’s strength and expertise in Institutional Sales and Trading to assist emerging growth companies with their investor relations objectives.
• Institutional investors are increasingly looking for access to emerging growth companies for direct investments, as well as to better understand looming risks to the public companies they own
• Growth-oriented companies are staying private longer, but need access to capital from institutional-type sources

Jill Voon
Private Company Access